On the Need to Determine the Contribution of Anti-Nucleocapsid Antibodies as Potential Contributors to COVID-19 Convalescent Plasma Efficacy

Historically the therapeutic potential of polyclonal passive immunotherapies in viral diseases has been related to antiviral neutralizing antibodies, but there is also considerable evidence that non-neutralizing antibodies can translate into clinical benefit as well. In the setting of SARS-CoV-2 inf...

Descripción completa

Detalles Bibliográficos
Autores principales: Focosi, Daniele, Franchini, Massimo, Casadevall, Arturo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Opinion
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9697776/
https://www.ncbi.nlm.nih.gov/pubmed/36366476
http://dx.doi.org/10.3390/v14112378

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9697776/
https://www.ncbi.nlm.nih.gov/pubmed/36366476
http://dx.doi.org/10.3390/v14112378

Ejemplares similares